Subscribe

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

Authored Items

High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
By Neil M. Iyengar, MD; Annalise Labatut, PharmD, BCOP
Videos
Case-Based Exchange
Stream the Case-Based Exchange Webinar: “High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer” to hear perspectives on markers of high-risk disease and practical treatment approaches from Neil Iyengar, MD, and Annalise Labatut, PharmD, BCOP, of the Winship Cancer Institute of Emory University. Topics include the role of the CDK4/6 inhibitor in adjuvant treatment.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.